Michael S Pepper

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/672744/publications.pdf

Version: 2024-02-01

296 papers 20,977 citations

72 h-index 138 g-index

303 all docs

303 docs citations

times ranked

303

22430 citing authors

#	Article	IF	CITATIONS
1	Equitable access to cell and gene therapies in South Africa: opportunities and hurdles. Gene Therapy, 2023, 30, 180-186.	2.3	8
2	Mesenchymal Stromal Cells: a Possible Reservoir for HIV-1?. Stem Cell Reviews and Reports, 2022, 18, 1253.	1.7	8
3	Slc7a8 Deletion Is Protective against Diet-Induced Obesity and Attenuates Lipid Accumulation in Multiple Organs. Biology, 2022, 11, 311.	1.3	6
4	High Resolution HLA â^1/4A, â^1/4B, â^1/4C, â^1/4DRB1, â^1/4DQA1, and â^1/4DQB1 Diversity in South African Populat Genetics, 2022, 13, 711944.	ions. Front 1.1	tiers in
5	Social Media and COVID-19â€"Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics. Antibiotics, 2022, 11, 445.	1.5	30
6	Coronavirus Host Genetics South Africa (COHG-SA) databaseâ€"a variant database for gene regions associated with SARS-CoV-2 outcomes. European Journal of Human Genetics, 2022, 30, 880-888.	1.4	6
7	Regenerative medicines: A new regulatory paradigm for South Africa. Biochimie, 2022, 196, 123-130.	1.3	1
8	A COVID-19 Vaccine: Big Strides Come with Big Challenges. Vaccines, 2021, 9, 39.	2.1	78
9	Step-by-step assembly and testing of a low-cost bioprinting solution for research and educational purposes. MethodsX, 2021, 8, 101186.	0.7	6
10	Characterization of Signalling Pathways That Link Apoptosis and Autophagy to Cell Death Induced by Estrone Analogues Which Reversibly Depolymerize Microtubules. Molecules, 2021, 26, 706.	1.7	5
11	Spectrum of MYO7A Mutations in an Indigenous South African Population Further Elucidates the Nonsyndromic Autosomal Recessive Phenotype of DFNB2 to Include Both Homozygous and Compound Heterozygous Mutations. Genes, 2021, 12, 274.	1.0	8
12	The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. Frontiers in Medicine, 2021, 8, 604087.	1.2	1
13	Similarities between Tumour Immune Response and Chronic Wound Microenvironment: Influence of Mesenchymal Stromal/Stem Cells. Journal of Immunology Research, 2021, 2021, 1-11.	0.9	9
14	Viruses, variants and vaccines. South African Medical Journal, 2021, 111, 409.	0.2	1
15	Single-Cell Transcriptome Analysis of Human Adipose-Derived Stromal Cells Identifies a Contractile Cell Subpopulation. Stem Cells International, 2021, 2021, 1-12.	1.2	2
16	Perspectives on establishing a public cord blood inventory in South Africa. Cytotherapy, 2021, 23, 548-557.	0.3	5
17	Molecular mechanisms underpinning sarcomas and implications for current and future therapy. Signal Transduction and Targeted Therapy, 2021, 6, 246.	7.1	42
18	Sexual Dimorphism in Changes That Occur in Tissues, Organs and Plasma during the Early Stages of Obesity Development. Biology, 2021, 10, 717.	1.3	7

#	Article	IF	CITATIONS
19	Inclusivity and diversity: Integrating international perspectives on stem cell challenges and potential. Stem Cell Reports, 2021, 16, 1847-1852.	2.3	5
20	An In Vitro and In Vivo Comparison of Osteogenic Differentiation of Human Mesenchymal Stromal/Stem Cells. Stem Cells International, 2021, 2021, 1-23.	1.2	20
21	The Genetic Discrimination Observatory: confronting novel issues in genetic discrimination. Trends in Genetics, 2021, 37, 951-954.	2.9	9
22	The impact of obesity on the cellular and molecular pathophysiology of COVID-19. South African Medical Journal, 2021, 111, 211.	0.2	1
23	When cells become medicines: A South African perspective. South African Medical Journal, 2021, 111, 1055.	0.2	2
24	Questions about the HELIX trial. The Lancet Global Health, 2021, 9, e1653.	2.9	1
25	Who is responsible for protecting my health during the COVID- 19 pandemic?. , 2021, , .		0
26	SARS-CoV-2 Variants, Vaccines, and Host Immunity. Frontiers in Immunology, 2021, 12, 809244.	2.2	176
27	The c-Myc/TBX3 Axis Promotes Cellular Transformation of Sarcoma-Initiating Cells. Frontiers in Oncology, 2021, 11, 801691.	1.3	3
28	Therapeutic hypothermia for neonatal hypoxic ischaemic encephalopathy should not be discontinued in low- and middle-income countries. South African Medical Journal, 2021, 111, 1168.	0.2	1
29	Fate of systemically and locally administered adipose-derived mesenchymal stromal cells and their effect on wound healing. Stem Cells Translational Medicine, 2020, 9, 131-144.	1.6	38
30	Barriers to Implementing Clinical Pharmacogenetics Testing in Sub-Saharan Africa. A Critical Review. Pharmaceutics, 2020, 12, 809.	2.0	23
31	Paediatric inflammatory multisystem syndrome: What should we look out for in South Africa?. South African Medical Journal, 2020, 110, 832.	0.2	1
32	Amplification of 3q26.2, 5q14.3, 8q24.3, 8q22.3, and 14q32.33 Are Possible Common Genetic Alterations in Oral Cancer Patients. Frontiers in Oncology, 2020, 10, 683.	1.3	12
33	The Role of Pref-1 during Adipogenic Differentiation: An Overview of Suggested Mechanisms. International Journal of Molecular Sciences, 2020, 21, 4104.	1.8	23
34	Adipogenesis: A Complex Interplay of Multiple Molecular Determinants and Pathways. International Journal of Molecular Sciences, 2020, 21, 4283.	1.8	152
35	Privacy rights of human research participants in South Africa must be taken seriously. South African Medical Journal, 2020, 110, 175.	0.2	5
36	A prospective observational study of developmental outcomes in survivors of neonatal hypoxic ischaemic encephalopathy in South Africa. South African Medical Journal, 2020, 110, 308.	0.2	17

#	Article	IF	Citations
37	The Deep Genome Project. Genome Biology, 2020, 21, 18.	3.8	30
38	Lessons Learned from Somatic Cell Nuclear Transfer. International Journal of Molecular Sciences, 2020, 21, 2314.	1.8	49
39	Resource allocation during COVID-19: A focus on vulnerable populations. South African Journal of Bioethics and Law, 2020, 13, 83.	0.1	5
40	Access to novel therapies for COVID-19 – distributive justice and Russian roulette?. South African Medical Journal, 2020, 110, 1156.	0.2	0
41	Rapid evolution of our understanding of the pathogenesis of COVID-19: Implications for therapy. South African Medical Journal, 2020, 110, 1180.	0.2	2
42	Research in COVID-19 times: The way forward. South African Medical Journal, 2020, 110, 756-758.	0.2	1
43	Molecular profile of tongue cancer in an 18â€yearâ€old female patient with no recognizable risk factor. Laryngoscope Investigative Otolaryngology, 2019, 4, 310-313.	0.6	5
44	Nonâ \in nucleoside reverse transcriptase inhibitor levels among HIV â \in exposed uninfected infants at the time of HIV PCR testing â \in " findings from a tertiary healthcare facility in Pretoria, South Africa. Journal of the International AIDS Society, 2019, 22, e25284.	1.2	4
45	Establishment and equilibrium levels of deleterious mutations in large populations. Scientific Reports, 2019, 9, 10384.	1.6	2
46	Stem cell therapy for neurological disorders. South African Medical Journal, 2019, 109, 70.	0.2	77
47	Transplantation of gene-modified haematopoietic stem cells: Application and clinical considerations. South African Medical Journal, 2019, 109, 64.	0.2	4
48	Human leukocyte antigen (HLA) diversity and clinical applications in South Africa. South African Medical Journal, 2019, 109, 29.	0.2	8
49	Heterogeneity of cell therapy products. South African Medical Journal, 2019, 109, 24.	0.2	3
50	HIV and haematopoiesis. South African Medical Journal, 2019, 109, 40.	0.2	34
51	The Effect of Early Rounds of ex vivo Expansion and Cryopreservation on the Adipogenic Differentiation Capacity of Adipose-Derived Stromal/Stem Cells. Scientific Reports, 2019, 9, 15943.	1.6	5
52	Safeguarding the future of genomic research in South Africa: Broad consent and the Protection of Personal Information Act No. 4 of 2013. South African Medical Journal, 2019, 109, 468.	0.2	23
53	The effect of medium supplementation and serial passaging on the transcriptome of human adipose-derived stromal cells expanded in vitro. Stem Cell Research and Therapy, 2019, 10, 253.	2.4	4
54	An Early Infant HIV Risk Score for Targeted HIV Testing at Birth. Pediatrics, 2019, 143, .	1.0	7

#	Article	IF	Citations
55	Reference Gene Expression in Adipose-Derived Stromal Cells Undergoing Adipogenic Differentiation. Tissue Engineering - Part C: Methods, 2019, 25, 353-366.	1.1	3
56	An optimistic vision for biosciences in South Africa: Reply to Thaldar et al. (2019). South African Journal of Science, 2019, 115, .	0.3	0
57	Gene and cell therapy in South Africa: Current status and future prospects. South African Medical Journal, 2019, 109, 12.	0.2	4
58	Heterozygosity of p16 expression in an oral squamous cell carcinoma with associated loss of heterozygosity and copy number alterations. Head and Neck, 2019, 41, E62-E65.	0.9	4
59	Comparison of human platelet lysate alternatives using expired and freshly isolated platelet concentrates for adipose-derived stromal cell expansion. Platelets, 2019, 30, 356-367.	1.1	22
60	Special edition of the SAMJ devoted to cell and gene therapy. South African Medical Journal, 2019, 109, 12719.	0.2	0
61	Effect of genetic variation in <i>UGT1A</i> and <i>ABCB1</i> on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Pharmacogenomics, 2018, 19, 17-29.	0.6	16
62	ASSAf consensus study on the ethical, legal and social implications of genetics and genomics in South Africa. South African Journal of Science, 2018, 114, .	0.3	6
63	Side Population: Its Use in the Study of Cellular Heterogeneity and as a Potential Enrichment Tool for Rare Cell Populations. Stem Cells International, 2018, 2018, 1-7.	1.2	7
64	Cell and gene therapies at the forefront of innovative medical care: Implications for South Africa. South African Medical Journal, 2018, 109, 20.	0.2	4
65	Ethical considerations in the application of cell and gene therapies in children. South African Medical Journal, 2018, 108, 1027.	0.2	4
66	Strategies for screening cord blood for a public cord blood bank in high HIV prevalence regions. Global Health, Epidemiology and Genomics, 2018, 3, e9.	0.2	8
67	Cystic fibrosis in South Africa: A changing diagnostic paradigm. South African Medical Journal, 2018, 108, 624.	0.2	5
68	Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape. Stem Cells Translational Medicine, 2018, 7, 643-650.	1.6	51
69	Human Leukocyte Antigen-A, B, C, DRB1, and DQB1 Allele and Haplotype Frequencies in a Subset of 237 Donors in the South African Bone Marrow Registry. Journal of Immunology Research, 2018, 2018, 1-8.	0.9	9
70	An in vitro and in vivo study on the properties of hollow polycaprolactone cell-delivery particles. PLoS ONE, 2018, 13, e0198248.	1.1	7
71	Deoxyribonucleic Acid Damage and Repair: Capitalizing on Our Understanding of the Mechanisms of Maintaining Genomic Integrity for Therapeutic Purposes. International Journal of Molecular Sciences, 2018, 19, 1148.	1.8	18
72	Targeting the aryl hydrocarbon receptor nuclear translocator complex with DMOG and Stemregenin 1 improves primitive hematopoietic stem cell expansion. Stem Cell Research, 2017, 21, 124-131.	0.3	13

#	Article	IF	CITATIONS
73	Impact of <i>CYP2D6</i> genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study. Pharmacogenomics, 2017, 18, 433-443.	0.6	18
74	Identification of transcription factors potentially involved in human adipogenesis inÂvitro. Molecular Genetics & Enomic Medicine, 2017, 5, 210-222.	0.6	24
75	AMLprofiler: A Diagnostic and Prognostic Microarray for Acute Myeloid Leukemia. Methods in Molecular Biology, 2017, 1633, 101-123.	0.4	3
76	Clinical Safety and Applications of Stem Cell Gene Therapy. Stem Cells in Clinical Applications, 2017, , 67-89.	0.4	0
77	Contrasting Views on the Role of Mesenchymal Stromal/Stem Cells in Tumour Growth: A Systematic Review of Experimental Design. Advances in Experimental Medicine and Biology, 2017, 1083, 103-124.	0.8	10
78	The Role of Reactive Oxygen Species in Adipogenic Differentiation. Advances in Experimental Medicine and Biology, 2017, 1083, 125-144.	0.8	26
79	Cancer Stem Cells in Head and Neck Carcinomas: Identification and Possible Therapeutic Implications. Advances in Experimental Medicine and Biology, 2017, 1083, 89-102.	0.8	5
80	The state of gene therapy research in Africa, its significance and implications for the future. Gene Therapy, 2017, 24, 581-589.	2.3	11
81	Cystic Fibrosis in the African Diaspora. Annals of the American Thoracic Society, 2017, 14, 1-7.	1.5	31
82	Whole-genome sequencing for an enhanced understanding of genetic variation among South Africans. Nature Communications, 2017, 8, 2062.	5.8	88
83	Reactive Oxygen Species and NOX Enzymes Are Emerging as Key Players in Cutaneous Wound Repair. International Journal of Molecular Sciences, 2017, 18, 2149.	1.8	88
84	The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer. International Journal of Molecular Sciences, 2017, 18, 1586.	1.8	301
85	Application of the AMLprofiler Diagnostic Microarray in the South African Setting. Stem Cells International, 2017, 2017, 1-8.	1.2	1
86	Exporting DNA – striking a balance between preventing exploitation and promoting innovation. South African Medical Journal, 2017, 107, 106.	0.2	3
87	Ownership and human tissue – the legal conundrum: A response to Jordaan's critique. South African Medical Journal, 2017, 107, 196.	0.2	0
88	Social justice and research using human biological material: A right to respond. South African Medical Journal, 2016, 106, 842.	0.2	0
89	Could we offer mitochondrial donation or similar assisted reproductive technology to South African patients with mitochondrial DNA disease?. South African Medical Journal, 2016, 106, 234.	0.2	4
90	CRISPR-Cas: Revolutionising genome engineering. South African Medical Journal, 2016, 106, 870.	0.2	1

#	Article	IF	Citations
91	Wharton's Jelly-Derived Mesenchymal Stromal Cells and Fibroblast-Derived Extracellular Matrix Synergistically Activate Apoptosis in a p21-Dependent Mechanism in WHCO1 and MDA MB 231 Cancer CellsIn Vitro. Stem Cells International, 2016, 2016, 1-17.	1.2	26
92	Making the Switch: Alternatives to Fetal Bovine Serum for Adipose-Derived Stromal Cell Expansion. Frontiers in Cell and Developmental Biology, 2016, 4, 115.	1.8	58
93	Fibroblast-Derived Extracellular Matrix Induces Chondrogenic Differentiation in Human Adipose-Derived Mesenchymal Stromal/Stem Cells in Vitro. International Journal of Molecular Sciences, 2016, 17, 1259.	1.8	44
94	Pharmacogenomics for infectious diseases in sub-Saharan Africa: Successes and opportunities. Applied & Translational Genomics, 2016, 9, 3-5.	2.1	7
95	The FitTrack Index as fitness indicator: AÂpilotÂstudy. Health SA Gesondheid, 2016, 21, 431-436.	0.3	1
96	Allelic variants of the Melanocortin 4 receptor (MC 4R) gene in a South African study group. Molecular Genetics & Cenomic Medicine, 2016, 4, 68-76.	0.6	10
97	Genome-wide analysis of gene expression during adipogenesis in human adipose-derived stromal cells reveals novel patterns of gene expression during adipocyte differentiation. Stem Cell Research, 2016, 16, 725-734.	0.3	107
98	Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade. OMICS A Journal of Integrative Biology, 2016, 20, 593-603.	1.0	20
99	Isolation and Characterization of Adipose-Derived Stromal Cells. Stem Cells in Clinical Applications, 2016, , 131-161.	0.4	2
100	Cord Blood Stem Cell Banking. Stem Cells in Clinical Applications, 2016, , 163-180.	0.4	2
101	Mitochondrial transfer: Implications for assisted reproductive technologies. Applied & Translational Genomics, 2016, 11, 40-47.	2.1	30
102	Novel flow cytometric approach for the detection of adipocyte subpopulations during adipogenesis. Journal of Lipid Research, 2016, 57, 729-742.	2.0	24
103	Human adipose derived mesenchymal stromal cells transduced with GFP lentiviral vectors: assessment of immunophenotype and differentiation capacity in vitro. Cytotechnology, 2016, 68, 2049-2060.	0.7	14
104	Cystic fibrosis on the African continent. Genetics in Medicine, 2016, 18, 653-662.	1.1	31
105	Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort. Pharmacogenomics Journal, 2016, 16, 566-572.	0.9	10
106	Biotechnology Innovators To Convene in Cape Town, South Africa: Pharmacogenetics and Precision Medicine Conference (April 7–9, 2016). OMICS A Journal of Integrative Biology, 2015, 19, 731-732.	1.0	0
107	HLA typing: Conventional techniques v. next-generation sequencing. South African Medical Journal, 2015, 106, 88.	0.2	5
108	A global comparative overview of the legal regulation of stem cell research and therapy: Lessons for South Africa. South African Journal of Bioethics and Law, 2015, 8, 12.	0.1	14

#	Article	IF	CITATIONS
109	Mitochondrial transfer: Ethical, legal and social implications in assisted reproduction. South African Journal of Bioethics and Law, 2015, 8, 32.	0.1	4
110	Progresses towards safe and efficient gene therapy vectors. Oncotarget, 2015, 6, 30675-30703.	0.8	163
111	Human Leukocyte Antigen Diversity: A Southern African Perspective. Journal of Immunology Research, 2015, 2015, 1-11.	0.9	30
112	Legislation governing pluripotent stem cells in South Africa. South African Journal of Bioethics and Law, 2015, 8, 23.	0.1	4
113	Gender and sexual diversity - changing paradigms in an ever-changing world. South African Medical Journal, 2015, 105, 746.	0.2	1
114	Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort. Applied & Translational Genomics, 2015, 5, 40-46.	2.1	8
115	Altered expression of platelet factor 4 and basic fibroblast growth factor correlates with the inhibition of tumor growth in mice. Biomedicine and Pharmacotherapy, 2015, 69, 186-190.	2.5	2
116	Biocompatibility and biodegradation of protein microparticle and film scaffolds made from kafirin (sorghum prolamin protein) subcutaneously implanted in rodent models. Journal of Biomedical Materials Research - Part A, 2015, 103, 2582-2590.	2.1	14
117	Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine. Drug Metabolism Reviews, 2015, 47, 111-123.	1.5	28
118	The Role of Reactive Oxygen Species in Mesenchymal Stem Cell Adipogenic and Osteogenic Differentiation: A Review. Stem Cells and Development, 2015, 24, 1150-1163.	1.1	472
119	Homing properties of mesenchymal stromal cells. Expert Opinion on Biological Therapy, 2015, 15, 477-479.	1.4	34
120	Constituting a public umbilical cord blood bank in South Africa. Bone Marrow Transplantation, 2015, 50, 615-616.	1.3	2
121	Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice. Journal of Virology, 2015, 89, 6761-6772.	1.5	30
122	Evaluation of predictive <i>CYP2C19</i> genotyping assays relative to measured phenotype in a South African cohort. Pharmacogenomics, 2015, 16, 1343-1354.	0.6	4
123	Priority pharmacogenetics for the African continent: focus on CYP450. Pharmacogenomics, 2014, 15, 385-400.	0.6	10
124	The correlation between the health-related fitness of healthy participants measured at home as opposed to fitness measured by sport scientists in a laboratory. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2014, 56, 235-239.	0.2	6
125	C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection. Applied & Translational Genomics, 2013, 2, 3-16.	2.1	84
126	Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Medical Genetics, 2013, 14, 20.	2.1	42

#	Article	IF	Citations
127	Mutations in C-C chemokine receptor type 5 (CCR5) in South African individuals. International Journal of Infectious Diseases, 2013, 17, e1148-e1153.	1.5	11
128	Special Issue $\hat{a}\in$ " Pharmacogenomics & Dersonalized medicine, Journal of Applied and Translational Genomics. Applied & Translational Genomics, 2013, 2, 1-2.	2.1	0
129	Establishing a Public Umbilical Cord Blood Stem Cell Bank for South Africa: An Enquiry into Public Acceptability. Stem Cell Reviews and Reports, 2013, 9, 752-763.	5.6	7
130	Opportunities and barriers to establishing a cell therapy programme in South Africa. Stem Cell Research and Therapy, 2013, 4, 54.	2.4	5
131	Cytochrome P450 pharmacogenetics in African populations. Drug Metabolism Reviews, 2013, 45, 253-275.	1.5	42
132	Curbing stem cell tourism in South Africa. Applied & Translational Genomics, 2013, 2, 22-27.	2.1	10
133	Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation. Nutrition Reviews, 2013, 71, 180-188.	2.6	103
134	ILâ€27 Inhibits Lymphatic Endothelial Cell Proliferation by STAT1â€Regulated Gene Expression. Microcirculation, 2013, 20, 555-564.	1.0	22
135	Adipocyte and adipogenesis. European Journal of Cell Biology, 2013, 92, 229-236.	1.6	463
136	University entrepreneurship in South Africa: Developments in technology transfer practices. Innovation: Management, Policy and Practice, 2013, 15, 205-214.	2.6	57
137	Stem cell research engenders interdisciplinary collaboration in science, ethics and religion. South African Journal of Science, 2012, 108, .	0.3	0
138	Genomic sovereignty and the African promise: mining the African genome for the benefit of Africa. Journal of Medical Ethics, 2012, 38, 474-478.	1.0	68
139	Pilot Social Feasibility Study for the Establishment of a Public Human Umbilical Cord Blood Stem Cell Bank in South Africa. Stem Cell Reviews and Reports, 2012, 8, 1066-1075.	5.6	6
140	Partial relief from the regulatory vacuum involving human tissues through enactment of chapter 8 of the National Health Act and regulations thereto. South African Medical Journal, 2012, 102, 736.	0.2	4
141	Cardiovascular pharmacogenetics., 2012, 133, 280-290.		19
142	Inhibition of hemangioma development in a syngeneic mouse model correlates with bcl-2 suppression and the inhibition of Akt kinase activity. Angiogenesis, 2012, 15, 131-139.	3.7	16
143	Hemangiomas - current therapeutic strategies. International Journal of Developmental Biology, 2011, 55, 431-437.	0.3	25
144	Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation. Current Pharmacogenomics and Personalized Medicine, 2011, 9, 191-207.	0.2	62

#	Article	IF	CITATIONS
145	Quantitative plasma analysis using automated online solidâ€phase extraction with column switching LCâ€MS/MS for characterising cytochrome P450 2D6 and 2C19 metabolism. Journal of Separation Science, 2011, 34, 1102-1110.	1.3	12
146	Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-κB and Prox1. Blood, 2010, 115, 418-429.	0.6	177
147	Cell-based therapy – navigating troubled waters. South African Medical Journal, 2010, 100, 286.	0.2	9
148	The healing power of stem cells: why we need rules. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2010, 52, 365-365.	0.2	1
149	Letter: Regaining Perspective on Stem Cells. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2010, 52, 164-164.	0.2	0
150	A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis, 2009, 12, 81-90.	3.7	53
151	IL-20 activates human lymphatic endothelial cells causing cell signalling and tube formation. Microvascular Research, 2009, 78, 25-32.	1.1	35
152	Lymphatic Endothelial Cells: Establishment of Primaries and Characterization of Established Lines. Methods in Molecular Biology, 2009, 467, 113-126.	0.4	4
153	Banning Private Stem Cell Banks: A Human Rights Analysis. South African Journal on Human Rights, 2009, 25, 126-151.	0.1	4
154	Circulating and imaging markers for angiogenesis. Angiogenesis, 2008, 11, 321-335.	3.7	40
155	Mixed Arterio-Venous Insufficiency in Random Skin Flaps in the Rat: Is the Application of Medicinal Leeches Beneficial?. Journal of Surgical Research, 2008, 150, 85-91.	0.8	12
156	Hypoxic Preconditioning Increases Skin Oxygenation and Viability but Does Not Alter VEGF Expression or Vascular Density. High Altitude Medicine and Biology, 2008, 9, 76-88.	0.5	7
157	Human Lymphatic Endothelial Cells Express Multiple Functional TLRs. Journal of Immunology, 2008, 180, 3399-3405.	0.4	98
158	The Lymphatic Vascular System in Lymphangiogenesis Invasion and Metastasis A Mathematical Approach., 2008,, 1-22.		3
159	Persistent ischemia impairs myofibroblast development in wound granulation tissue: A new model of delayed wound healing. Wound Repair and Regeneration, 2007, 15, 809-816.	1.5	36
160	Progressive tissue injury in burns is reduced by rNAPc2. Burns, 2006, 32, 957-963.	1.1	21
161	Tetracycline-Regulated Expression of VEGF-A in Beta Cells Induces Angiogenesis: Improvement of Engraftment following Transplantation. Cell Transplantation, 2006, 15, 621-636.	1.2	18
162	Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. Journal of Pathology, 2006, 209, 34-43.	2.1	74

#	Article	IF	Citations
163	Obesity in South Africa. Obesity Reviews, 2006, 7, 315-322.	3.1	64
164	Immunohistochemical quantification of lymph vessels, VEGF-C and VEGF receptor 3 in human sarcomas. Histopathology, 2006, 49, 87-88.	1.6	6
165	Bovine microvascular endothelial cells immortalized with human telomerase. Journal of Cellular Biochemistry, 2006, 98, 267-286.	1.2	25
166	Lymphatic vessel density in the neoplastic progression of Barrett's oesophagus to adenocarcinoma. Journal of Clinical Pathology, 2006, 59, 191-195.	1.0	19
167	First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. British Journal of Cancer, 2006, 95, 1611-1625.	2.9	185
168	Novel tempeh (fermented soyabean) isoflavones inhibit in vivo angiogenesis in the chicken chorioallantoic membrane assay. British Journal of Nutrition, 2005, 93, 317-323.	1.2	87
169	Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells. Oncogene, 2005, 24, 1689-1697.	2.6	44
170	Lymphangiogenesis in human gynaecological cancers. Angiogenesis, 2005, 8, 137-145.	3.7	16
171	Downregulation of vascular endothelial-cadherin expression is associated with an increase in vascular tumor growth and hemorrhagic complications. Thrombosis and Haemostasis, 2005, 93, 1041-1046.	1.8	27
172	Polymorphisms in the endothelial nitric oxide synthase gene and the tendency for aneurysm rupture. Journal of Neurosurgery, 2005, 102, 433.	0.9	1
173	Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin αvβ3 in Angiogenesis In vitro: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and αvβ3 Are Critical. Cancer Research, 2005, 65, 9377-9387.	0.4	65
174	Lymphatic Vessel Density and Vascular Endothelial Growth Factor-C Expression Correlate with Malignant Behavior in Human Pancreatic Endocrine Tumors. Clinical Cancer Research, 2004, 10, 6919-6928.	3.2	70
175	Hereditary Vascular Anomalies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1578-1590.	1.1	57
176	Visualizing Function in the Tumor-Associated Lymphatic System. Lymphatic Research and Biology, 2004, 2, 165-172.	0.5	10
177	Haemangiomas are formed by cells expressing high levels of $\hat{l}\pm v\hat{l}^2$ 3 integrin and lacking acetylated LDL uptake. Journal of Pathology, 2004, 203, 700-709.	2.1	8
178	8-prenylnaringenin, a novel phytoestrogen, inhibits angiogenesis in vitro and in vivo. Journal of Cellular Physiology, 2004, 199, 98-107.	2.0	54
179	Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C. Journal of Cell Science, 2004, 117, 2745-2756.	1.2	73
180	Generation and Characterization of Telomerase-Transfected Human Lymphatic Endothelial Cells with an Extended Life Span. American Journal of Pathology, 2004, 165, 11-24.	1.9	90

#	Article	IF	Citations
181	Active-site inactivated FVIIa decreases thrombosis and necrosis in a random skin flap model of acute ischemia. Journal of Surgical Research, 2004, 122, 263-273.	0.8	12
182	Lymphangiogenesis and tumour metastasis. Novartis Foundation Symposium, 2004, 256, 112-31; discussion 132-6, 259-69.	1.2	6
183	ÂvÂ3 and $\hat{l}\pm v\hat{l}^2$ 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis, 2003, 6, 105-119.	3.7	183
184	Lymphangiogenesis and tumor metastasis. Cell and Tissue Research, 2003, 314, 167-177.	1.5	170
185	Familial predisposition to tufted angioma: identification of blood and lymphatic vascular components. Clinical Genetics, 2003, 63, 393-399.	1.0	17
186	Ets 1 is expressed in capillary blood vessels but not in lymphatics. Journal of Pathology, 2003, 200, 561-567.	2.1	19
187	Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. Journal of Pathology, 2003, 201, 544-554.	2.1	127
188	Lymphatic endothelium. Journal of Cell Biology, 2003, 163, 209-213.	2.3	169
189	Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-CÎ"NÎ"C- and VEGF-A-induced angiogenesis in vitro. Experimental Cell Research, 2003, 285, 286-298.	1.2	39
190	Literature Watch. Lymphatic Research and Biology, 2003, 1, 245-249.	0.5	0
191	VEGF is a chemoattractant for FGF-2–stimulated neural progenitors. Journal of Cell Biology, 2003, 163, 1375-1384.	2.3	188
192	RETROVIRAL TRANSDUCTION OF PANCREATIC BETACELLS BY VEGF-164 IMPROVES GLYCEMIC CONTROL IN A SYNGENEIC MODEL OF ISLET CELL TRANSPLANTATION. Transplantation, 2003, 76, S60-S61.	0.5	0
193	Lymphangiogenesis and tumor metastasis. Thrombosis and Haemostasis, 2003, 90, 591-597.	1.8	44
194	Role of the Plasminogen Activator-Plasmin System in Angiogenesis. , 2003, , 269-290.		0
195	A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. British Journal of Cancer, 2002, 87, 537-544.	2.9	73
196	Molecular characterization of lymphatic endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16069-16074.	3.3	436
197	Heterogeneity of Smooth Muscle Cell Populations Cultured From Pig Coronary Artery. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1093-1099.	1.1	133
198	Mesenchymal Cells Potentiate Vascular Endothelial Growth Factor-Induced Angiogenesis. Experimental Cell Research, 2002, 280, 179-191.	1.2	60

#	Article	IF	Citations
199	Lymphatic dissemination of tumour cells and the formation of micrometastases. Lancet Oncology, The, 2002, 3, 44-52.	5.1	78
200	Microscopy: an art?. Nature Reviews Molecular Cell Biology, 2002, 3, 133-137.	16.1	9
201	Angiogenesis-Regulating Cytokines. , 2002, , 7-40.		2
202	Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis. Cancer Research, 2002, 62, 603-8.	0.4	54
203	Increased angiostatin levels in bronchoalveolar lavage fluids from ARDS patients and from human volunteers after lung instillation of endotoxin. Thrombosis and Haemostasis, 2002, 87, 966-71.	1.8	3
204	FGF-2 Promotes Disassembly of Actin Cytoskeleton and Shape Changes in Murine Vascular Cells. Microvascular Research, 2001, 61, 211-214.	1.1	3
205	Signalling properties of an HIV-encoded angiogenic peptide mimicking vascular endothelial growth factor activity. Biochemical Journal, 2001, 353, 569.	1.7	25
206	Signalling properties of an HIV-encoded angiogenic peptide mimicking vascular endothelial growth factor activity. Biochemical Journal, 2001, 353, 569-578.	1.7	25
207	Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. FEBS Journal, 2001, 268, 5530-5540.	0.2	89
208	Lectin-deficient TNF mutants display comparable anti-tumour but reduced pro-metastatic potential as compared to the wild-type molecule. International Journal of Cancer, 2001, 91, 543-549.	2.3	8
209	Response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: Relevance to the regulation of angiogenesis. Journal of Cellular Biochemistry, 2001, 82, 619-633.	1.2	45
210	Lymphangiogenesis and Lymph Node Microdissemination. Gynecologic Oncology, 2001, 82, 1-3.	0.6	18
211	Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO Journal, 2001, 20, 672-682.	3.5	808
212	Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemia. Gene Therapy, 2001, 8, 523-533.	2.3	107
213	Inhibition of Endothelial Wound Repair by Dominant Negative Connexin Inhibitors. Molecular Biology of the Cell, 2001, 12, 831-845.	0.9	94
214	Role of the Matrix Metalloproteinase and Plasminogen Activator–Plasmin Systems in Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1104-1117.	1.1	701
215	Vascular Morphogenesis in the Mammary Gland: Introduction and Overview., 2001,, 3-24.		1
216	Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2., 2001, 268, 5530.		4

#	Article	IF	CITATIONS
217	Growth Factor Regulation of Physiologic Angiogenesis in the Mammary Gland. , 2001, , 25-40.		0
218	Lymphangiogenesis and tumor metastasis: myth or reality?. Clinical Cancer Research, 2001, 7, 462-8.	3.2	250
219	Extracellular proteolysis and angiogenesis. Thrombosis and Haemostasis, 2001, 86, 346-55.	1.8	61
220	Synergistic induction of t-PA by vascular endothelial growth factor and basic fibroblast growth factor and localization of t-PA to Weibel-Palade bodies in bovine microvascular endothelial cells. Thrombosis and Haemostasis, 2001, 86, 702-9.	1.8	9
221	Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. Journal of Pharmacology and Experimental Therapeutics, 2001, 299, 1073-85.	1.3	86
222	Elevated levels of angiogenic cytokines in the plasma of cancer patients. International Journal of Cancer, 2000, 85, 40-45.	2.3	78
223	New role for tRNA and its fragment purified from human urinary bladder carcinoma conditioned medium: Inhibition of endothelial cell growth. , 2000, 76, 109-117.		25
224	Regulation of VEGF and VEGF receptor expression in the rodent mammary gland during pregnancy, lactation, and involution. Developmental Dynamics, 2000, 218, 507-524.	0.8	63
225	Thrombospondin-1 Is Downregulated by Anoxia and Suppresses Tumorigenicity of Human Glioblastoma Cells. Journal of Experimental Medicine, 2000, 191, 1789-1798.	4.2	102
226	Posttranscriptional Stimulation of Endothelial Cell Matrix Metalloproteinases 2 and 1 by Endothelioma Cells. Experimental Cell Research, 2000, 258, 384-394.	1.2	43
227	Hypoxia-Inducible Angiopoietin-2 Expression Is Mimicked by Iodonium Compounds and Occurs in the Rat Brain and Skin in Response to Systemic Hypoxia and Tissue Ischemia. American Journal of Pathology, 2000, 156, 2077-2089.	1.9	102
228	CHARACTERIZATION OF NOVEL CLONAL MURINE ENDOTHELIAL CELL LINES WITH AN EXTENDED LIFE SPAN. In Vitro Cellular and Developmental Biology - Animal, 2000, 36, 299.	0.7	7
229	Lymphangiogenesis and tumor metastasis: more questions than answers. Lymphology, 2000, 33, 144-7.	0.1	9
230	Retinoic Acid Regulates Arterial Smooth Muscle Cell Proliferation and Phenotypic Features In Vivo and In Vitro Through an RARα-Dependent Signaling Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1430-1436.	1.1	95
231	Pediatric medulloblastoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density. Journal of Neuro-Oncology, 1999, 45, 103-110.	1.4	41
232	Chromogranin A Alters Ductal Morphogenesis and Increases Deposition of Basement Membrane Components by Mammary Epithelial Cells in Vitro. Biochemical and Biophysical Research Communications, 1999, 259, 563-568.	1.0	10
233	LymphangiogenÃ"se et activité biologique du facteur de croissance vasculaire endothélial-C. Société De Biologie Journal, 1999, 193, 159-163.	0.3	3
234	Endothelial cell integrin alpha5beta1 expression is modulated by cytokines and during migration in vitro. Journal of Cell Science, 1999, 112 (Pt 4), 569-78.	1.2	18

#	Article	IF	CITATIONS
235	Roles of hepatocyte growth factor/scatter factor and transforming growth factor-beta1 in mammary gland ductal morphogenesis. Journal of Mammary Gland Biology and Neoplasia, 1998, 3, 133-150.	1.0	62
236	Both TNF receptors are required for direct TNF-mediated cytotoxicity in microvascular endothelial cells. European Journal of Immunology, 1998, 28, 3577-3586.	1.6	56
237	Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity., 1998, 177, 439-452.		153
238	Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology, 1998, 32, 133-138.	1.6	262
239	Regulation of Vascular Endothelial Growth Factor Receptor-2 (Flk-1) Expression in Vascular Endothelial Cells. Experimental Cell Research, 1998, 241, 414-425.	1.2	87
240	7Phytoestrogens and inhibition of angiogenesis. Bailliere's Clinical Endocrinology and Metabolism, 1998, 12, 649-666.	1.0	110
241	Regulation of Angiopoietin-2 mRNA Levels in Bovine Microvascular Endothelial Cells by Cytokines and Hypoxia. Circulation Research, 1998, 83, 852-859.	2.0	339
242	Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11709-11714.	3.3	472
243	Plasminogen Activator Expression in Rat Arterial Smooth Muscle Cells Depends on Their Phenotype and Is Modulated by Cytokines. Circulation Research, 1998, 82, 1086-1093.	2.0	42
244	FGFâ€2 stimulates migration of Kaposi's sarcomaâ€like vascular cells by HGFâ€dependent relocalization of the urokinase receptor. FASEB Journal, 1998, 12, 1027-1034.	0.2	22
245	Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood, 1998, 92, 4730-41.	0.6	135
246	Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine and Growth Factor Reviews, 1997, 8, 21-43.	3.2	649
247	Manipulating Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 605-619.	1.1	244
248	PDGF-BB increases endothelial migration and cord movements during angiogenesis in vitro. Journal of Cellular Biochemistry, 1997, 64, 403-413.	1.2	60
249	Induction of epithelial branching tubulogenesis in vitro. , 1997, 173, 152-161.		34
250	Polyoma Middle T-induced Vascular Tumor Formation: The Role of the Plasminogen Activator/Plasmin System. Journal of Cell Biology, 1997, 137, 953-963.	2.3	65
251	VASCULAR ENDOTHELIAL GROWTH FACTOR IS INCREASED IN DEVASCULARIZED RAT ISLETS OF LANGERHANS IN VITRO1. Transplantation, 1997, 63, 436-443.	0.5	65
252	Endothelial Cells of the Human Microvasculature Express Epidermal Fatty Acid–Binding Protein. Circulation Research, 1997, 81, 297-303.	2.0	76

#	Article	IF	Citations
253	PDGF-BB increases endothelial migration on cord movements during angiogenesis in vitro. Journal of Cellular Biochemistry, 1997, 64, 403-13.	1.2	11
254	Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Research, 1997, 57, 2916-21.	0.4	362
255	Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. Journal of Cell Science, 1997, 110 (Pt 18), 2293-302.	1.2	35
256	Angiogenesis: A Paradigm for Balanced Extracellular Proteolysis during Cell Migration and Morphogenesis. Enzyme & Protein, 1996, 49, 138-162.	1.6	211
257	Positive and Negative Regulation of Angiogenesis: From Cell Biology to the Clinic. Vascular Medicine, 1996, 1, 259-266.	0.8	46
258	Modulation of Clusterin Gene Expression in the Rat Mammary Gland during Pregnancy, Lactation, and Involution 1. Biology of Reproduction, 1996, 55, 1213-1220.	1.2	23
259	Transforming Growth Factor \hat{l}^21 Down-regulates Vascular Endothelial Growth Factor Receptor 2/flk-1 Expression in Vascular Endothelial Cells. Journal of Biological Chemistry, 1996, 271, 11500-11505.	1.6	144
260	An Antisense Oligonucleotide to the Notch Ligand Jagged Enhances Fibroblast Growth Factor-induced Angiogenesis in Vitro. Journal of Biological Chemistry, 1996, 271, 32499-32502.	1.6	134
261	Angiogenesis-Regulating Cytokines: Activities and Interactions. Current Topics in Microbiology and Immunology, 1996, 213 (Pt 2), 31-67.	0.7	45
262	Inhibitors of Angiogenesis in Human Urine. , 1996, , 213-227.		0
263	Three-Dimensional In Vitro Assay of Endothelial Cell Invasion and Capillary Tube Morphogenesis. , 1996, , 79-110.		2
264	Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro. Laboratory Investigation, 1996, 75, 249-62.	1.7	35
265	Vascular Endothelial Growth Factor Increases Urokinase Receptor Expression in Vascular Endothelial Cells. Journal of Biological Chemistry, 1995, 270, 9709-9716.	1.6	237
266	Modulation of Hepatocyte Growth Factor and c-met in the Rat Mammary Gland during Pregnancy, Lactation, and Involution. Experimental Cell Research, 1995, 219, 204-210.	1.2	51
267	Hepatocyte growth factor stimulates extensive development of branching duct-like structures by cloned mammary gland epithelial cells. Journal of Cell Science, 1995, 108 (Pt 2), 413-30.	1.2	80
268	Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. Journal of Cellular Biochemistry, 1994, 55, 419-434.	1.2	82
269	The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature, 1994, 368, 237-239.	13.7	700
270	Membrane proteases in focus. Nature, 1994, 370, 14-15.	13.7	188

#	Article	IF	Citations
271	In Vitro Angiogenic and Proteolytic Properties of Bovine Lymphatic Endothelial Cells. Experimental Cell Research, 1994, 210, 298-305.	1.2	102
272	Angiogenesis in Vitro: Cytokine Interactions and Balanced Extracellular Proteolysis., 1994,, 149-170.		6
273	Biphasic Effect of Transforming Growth Factor- \hat{l}^21 on in Vitro Angiogenesis. Experimental Cell Research, 1993, 204, 356-363.	1.2	321
274	Differential expression of gap junction connexins in endocrine and exocrine glands Endocrinology, 1993, 133, 2371-2378.	1.4	178
275	Upregulation of urokinase receptor expression on migrating endothelial cells. Journal of Cell Biology, 1993, 122, 673-684.	2.3	276
276	Genistein, a dietary-derived inhibitor of in vitro angiogenesis Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 2690-2694.	3.3	696
277	Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochemical and Biophysical Research Communications, 1992, 189, 824-831.	1.0	798
278	Coupling and connexin 43 expression in microvascular and large vessel endothelial cells. American Journal of Physiology - Cell Physiology, 1992, 262, C1246-C1257.	2.1	99
279	Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. Journal of Cellular Physiology, 1992, 153, 129-139.	2.0	105
280	Basic fibroblast growth factor increases junctional communication and connexin 43 expression in microvascular endothelial cells. Journal of Cellular Physiology, 1992, 153, 196-205.	2.0	103
281	Modulation of angiogenesis in vitro. Exs, 1992, 61, 129-136.	1.4	22
282	Proteolytic balance and capillary morphogenesis in vitro. Exs, 1992, 61, 137-145.	1.4	12
283	Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. Journal of Biological Chemistry, 1992, 267, 20493-6.	1.6	166
284	Plasminogen activator inhibitor-1 is induced in microvascular endothelial cells by a chondrocyte-derived transforming growth factor-beta. Biochemical and Biophysical Research Communications, 1991, 176, 633-638.	1.0	27
285	Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochemical and Biophysical Research Communications, 1991, 181, 902-906.	1.0	584
286	In vivo modulation of connexin 43 gene expression and junctional coupling of pancreatic B-cells. Experimental Cell Research, 1991, 192, 469-480.	1.2	84
287	Chondrocytes inhibit endothelial sprout formation in vitro: Evidence for involvement of a transforming growth factor-beta. Journal of Cellular Physiology, 1991, 146, 170-179.	2.0	72
288	Proteolytic balance and capillary morphogenesis. Cell Differentiation and Development, 1990, 32, 319-327.	0.4	185

#	Article	IF	CITATIONS
289	Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro Journal of Cell Biology, 1990, 111, 743-755.	2.3	449
290	Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell, 1990, 62, 435-445.	13.5	437
291	Junctional communication is induced in migrating capillary endothelial cells Journal of Cell Biology, 1989, 109, 3027-3038.	2.3	109
292	Induction of angiogenesis in vitro by vanadate, an inhibitor of phosphotyrosine phosphatases. Journal of Cellular Physiology, 1988, 134, 460-466.	2.0	77
293	Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells Journal of Cell Biology, 1987, 105, 2535-2541.	2.3	264
294	Phorbol ester induces cultured endothelial cells to invade a fibrin matrix in the presence of fibrinolytic inhibitors. Journal of Cellular Physiology, 1987, 132, 509-516.	2.0	124
295	Dance-a suitable form of exercise? A physiological appraisal. South African Medical Journal, 1984, 66, 883-8.	0.2	1
296	Differential expression of gap junction connexins in endocrine and exocrine glands. , 0, .		51